Valneva
the only inactivated vaccine in clinical development in with | Valneva
Company
Deck Type
IPO
Sector
Industry
Deck date
April 2021
Slide
26 of 41
Related slides by other companies
GreenLight
SPAC
August 2021
influenza vaccines in development success of covid vaccines has renewed interest in influenza | GreenLight
Erasca
Investor Presentation
January 2024
clinical development plan generates multiple ways to win for patients | Erasca
BenevolentAI
Investor Presentation
October 2022
ben phase progressing phase double blind placebo controlled in patient two part clinical study day day day day active recruiting sites in the in a further sites under approval recruitment completion anticipated our intention is to to partner this asset with a pharmaceutical company that has a focus in dermatology for continued clinical development and if approved our intention is to out development and of ben following completion of this trial with key big and dermatology specialists as potential part | BenevolentAI
AstraZeneca
Investor Presentation
March 2022
| AstraZeneca
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io